Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Original Article

SGLT2 inhibitors and cardiorenal events in non-albuminuric kidney disease

Sodium-Glucose Cotransporter-2 Inhibitors and Cardiorenal Events in Nonalbuminuric Kidney Disease.

Kidney international reports

Citation & Authors

Kidney Int Rep. 2026;11(3):103756.

Fu-Shun Yen; Keong Chong; Chien-Wei Huang; James Cheng-Chung Wei; Jia-Sin Liu; Yi-Ling Wu; Chih-Ming Chen; Chii-Min Hwu; Chih-Cheng Hsu

ABSTRACT · CHINESE TRANSLATION

Translated abstract

Translated from the licensed abstract via the Chinese version. This is not an official journal translation.

Preface

Most patients with type 2 diabetes and chronic kidney disease do not have albuminuria, but data on the potential benefits of SGLT2 inhibitors in this population are limited.

method

This population-based cohort study used Taiwan’s National Health Insurance Research Database from May 1, 2016, to December 31, 2021, to investigate associations between SGLT2 inhibitor use and outcomes in patients with type 2 diabetes and nonalbuminuric chronic kidney disease. Cox proportional hazards models compared the study and control groups.

result

Follow-up lasted 3 years. In the prematching intention-to-treat model, SGLT2 inhibitor use versus nonuse was associated with lower risks of dialysis (aHR 0.21; 95% CI 0.10–0.44; P<0.001), progression to macroalbuminuria (0.86; 0.79–0.94; P=0.001), major adverse cardiovascular events (0.85; 0.76–0.95; P=0.005), acute kidney injury (0.68; 0.56–0.82; P<0.001), and all-cause mortality (0.63; 0.52–0.76; P<0.001). Multivariable analyses after propensity score matching showed lower risks of progression to macroalbuminuria (0.84; 0.73–0.97; P=0.015) and all-cause mortality (0.40; 0.28–0.59; P<0.001) in users.

Conclusion

This nationwide cohort found that SGLT2 inhibitor use in patients with type 2 diabetes and nonalbuminuric chronic kidney disease was significantly associated with lower risks of progression to macroalbuminuria and all-cause mortality.

Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.

Original work license:CC BY ↗;Translations are subject to the same licensing conditions.